Canadian Pulmonary Fibrosis Foundation

Media Kit

Here are resources for members of the media. If you have any questions or wish to schedule an interview, please contact our media team.

Key Contacts

CPFF Board of Directors

Executive Director, Canadian Pulmonary Fibrosis Foundation

Board Chair, Canadian Pulmonary Fibrosis Foundation

Medical Professionals

Chair of CPFF Medical Advisory Council, Founding Chair of Canadian Thoracic Society’s Clinical Assembly on Interstitial Lung Diseases, Director of the University of Calgary Interstitial Lung Disease Program.

Division Head of Rheumatology at St. Joseph’s Health Centre in London, Ontario. Professor of Medicine in the Division of Rheumatology and also Epidemiology and Biostatistics at the University of Western Ontario, Schulich School of Medicine, London, Ontario.

Patients and Caregivers

Patient, Vancouver, BC, CPFF Board of Directors
Misdiagnosed and delayed diagnosis.

Two people in hats standing outdoors — Brad & Heidi Schollengberg

Patient & Caregiver, Winnipeg, MB
Lung transplant recipient.

Patient, Toronto, ON, CPFF Board of Directors
Lung transplant recipient.

Patient, Nova Scotia
Misdiagnosed, PF treatment was ineffective. Lung transplant recipient.

Woman standing in park looking at camera, wearing a blue PF tshirt. — Jackie Clarke

Carries the gene for PF, Calgary, AB
Pulmonary fibrosis runs in her family.

Patient, Avonmore, ON,
Living with pulmonary fibrosis.

PF Caregiver, Montreal, QC
Recently lost father to PF.

Media Release

New treatments in development offer hope for thousands of Canadian pulmonary fibrosis (PF) patients after nearly a decade of anticipation

With ongoing investigation into PF and other diseases that inflame and permanently scar lung tissue, researchers are hoping to stop the disease in its tracks and ease the suffering of more than 30,000 Canadians who struggle to breathe.

September 5, 2024 (Markham, ON). During Pulmonary Fibrosis (PF) Month, the Canadian Pulmonary Fibrosis Foundation (CPFF) is shining a light on the promise of impending medical breakthroughs that offer new hope for thousands of Canadians suffering from this disease. Innovative new treatments and medications are being developed to reduce coughs and stop or potentially reverse lung damage caused by PF, giving hope where there has traditionally been little. These advances hold the potential to significantly improve the quality of life for those affected by this devastating lung disease.

Potential to stop and reverse lung scarring a game changer for PF patients

After a decade since new treatments for PF were approved, there are exciting new opportunities in the drug development pipeline. Early results show that one medication may be able to stop PF – a deadly lung disease that damages and scars lung tissue irreversibly and reduces oxygen flow to the body – from killing more than 3,000 Canadians annually. Another medication is showing significant progress in reducing persistent cough, a symptom reported by 80 per cent of PF patients.

Read the full media release.